China-based Ablaze Pharma and Yonghe Pharmaceutical have struck a partnership agreement for the research and development (R&D) and commissioned manufacturing of targeted radiotherapy (TRT). Yonghe, Ablaze’s Contract Development and Manufacturing Organization (CDMO) partner, will provide R&D and cGMP-compliant manufacturing services from the pre-clinical to clinical stages.
Company Background and Partnership Details
Founded in 2021, Ablaze is a clinical-stage biopharmaceutical company focused on developing TRT to benefit cancer patients in China. The company has partnered with US firm RayzeBio, obtaining exclusive rights to its products in Greater China. Yonghe, meanwhile, is engaged in the manufacturing and marketing of radiopharmaceuticals, with a product pipeline consisting of 14 radioisotope drugs. This partnership positions Ablaze to leverage Yonghe’s expertise in radiopharmaceuticals to advance its TRT development efforts.
Future Prospects and Strategic Implications
The collaboration between Ablaze Pharma and Yonghe Pharmaceutical marks a significant step in the development of targeted radiotherapy solutions. By combining Ablaze’s focus on TRT with Yonghe’s manufacturing and marketing capabilities, the partnership aims to enhance the availability and accessibility of innovative cancer treatments in China. This strategic move underscores the commitment of both companies to improving patient outcomes and addressing significant unmet medical needs in oncology.-Fineline Info & Tech
